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TrkC mediates many aspects of growth and development in
the central nervous system. TrkC is expressed in a variety of
non-neuronal tissues as well as human cancers. TrkC overex-
pression may drive tumorigenesis, invasion, and metastatic
capability in cancer cells. However, relatively little is known
about whether TrkC activity is also essential to maintain the
malignant properties in human tumors. TrkC expression leads
to the constitutive activation of two major effector pathways,
namely the Ras-MAP kinase (MAPK) mitogenic pathway and
the phosphatidylinositol 3-kinase (PI3K)-AKTpathwaymediat-
ing cell survival. However, it remains unclear how TrkC acti-
vates Ras-Erk1/2 and/or PI3K-Akt cascades. Here we define
some aspects of themolecularmechanisms regulating TrkC-de-
pendent Ras-Erk1/2 and PI3K/Akt activation. We show that
endogenous TrkC associated with c-Src in human and mouse
cancer cells which express TrkC. TrkC-c-Src complexes were
also detected in primary human breast cancer tissues. Suppres-
sion of c-Src by RNA interference in highly metastatic 4T1
mammary cancer cells, which express endogenous TrkC,
resulted inmarkedly decreased expression of cyclinD1 and sup-
pression of activation of Ras-Erk1/2 and PI3K-Akt. Moreover,
inhibition of c-Src expression almost completely blocks colony
formation of 4T1 cells in soft agar. Furthermore, in c-Src-defi-
cient SYF cells, TrkC failed to activate the PI3K-Atk pathway,
but not the Ras-Erk1/2 pathway. Therefore these data indicate
that TrkC induces the PI3K-Akt cascade through the activation
of c-Src.
Neurotrophins constitute a family of structurally related
growth factors that regulate growth, differentiation, and sur-
vival of neurons (1–4), as well as in some non-neuronal cells
(5–7). This family includes nerve growth factor (NGF),2 brain-
derived neurotrophic factor (BDNF), neurotrophin-3, and neu-
rotrophin-4 (1, 2). Receptors for neurotrophins include the Trk
family of receptor-tyrosine kinases (RTKs). TrkA preferentially
binds NGF, TrkB binds BDNF, and neurotrophin-4/5, and
TrkC binds neurotrophin-3 (8). Neurotrophins and their cor-
responding receptors have been shown to induce a variety of
pleiotropic responses in malignant cells, including enhanced
tumor invasiveness and chemotaxis (9–13). Also, neurotro-
phins and their receptors are important in the regulation of
angiogenesis (14), mitogenic signals, facilitating tumor growth
(15), prevention of apoptosis (16), and cell spreading and
metastasis (17). Trk receptors are frequently overexpressed in
pancreatic tumors, thyroid tumors, breast tumors, lung tumors,
melanomas, and prostatic tumors (11, 13, 18–27).
TrkC mediates many aspects of growth and development in
the central nervous system (13). A variety of non-neuronal tis-
sues have been shown to express TrkC (13, 27–30); however,
relatively little is known about whether TrkC activity is also
essential to maintain the malignant properties in human
tumors. Interestingly, recent sequence analysis of the tyrosine
kinome in colorectal cancers has revealed five point mutations
in the trkC gene, both within its kinase-encoding domain (9).
The effect of the trkCmutations on kinase function remains to
be determined, but their positions within each protein suggest
that many of them may be activating in nature.
TrkC is activated by cell surface ligand-mediated oligomer-
ization, which facilitates autophosphorylation of TrkC cyto-
plasmic tyrosine residues 516, 705, 709, 710, and 820 and sub-
sequent kinase activation (31–33). Several adapter molecules
and protein-tyrosine kinase (PTK) substrates have been linked
toTrkC signal transduction. PhosphorylatedTrkC tyrosine 516
binds the adaptor protein Src-homology/collagen (SHC) via the
SH2 domain of the latter (34), and is also the site of association
with the p85 subunit of phosphoinositol 3-kinase (PI3K) (31,
35). Activated SHC recruits growth factor receptor-bound pro-
tein 2 (GRB2), an adaptor protein, as well as the RAS guanine
nucleotide exchange factor Son-of-sevenless (Sos) to activate
the RAS-RAF1 pathway (36, 37). Phosphorylated PI3K medi-
ates activation of the protein kinase B (Akt/PKB) pathway (38).
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Phosphorylated NTRK3 tyrosine 820 binds phospholipase-C
(PLC) (39), resulting in the activation of protein kinase C
(PKC) (39–41).
The congenital fibrosarcoma t(12, 15)(p13;q25) rearrange-
ment splices the ETV6 (TEL) gene on chromosome 12p13 in-
framewith theNTRK3 (TrkC) neurotrophin-3 receptor gene on
chromosome 15q25. Resultant ETV6-NTRK3 fusion tran-
scripts encode the helix-loop-helix (HLH) dimerization
domain of ETV6 fused to the protein-tyrosine kinase (PTK)
domain of NTRK3. Expression of the ETV6-NTRK3 fusion
protein is associated with constitutively high levels of phospho-
rylatedMek1 and Akt, even in the absence of serum.Moreover,
ETV6-NTRK3-expressing cells show serum-independent ele-
vation of cyclin D1 protein. Inhibition of either the Ras-Erk1/2
MAP kinase or the PI3K-Akt pathway alone completely blocks
colony formation of ETV6-NTRK3-expressing cells in soft agar
assays. Furthermore, the constitutive expression of cyclin D1
protein in ETV6-NTRK3-expressing cells can be down-regu-
lated by MEK1 or PI3K inhibition. However, only inhibition of
the Ras-Erk1/2 pathway led to persistent down-regulation of
cyclin D1 levels in cells expressing ETV6-NTRK3 (42).
c-Src is known to activate the PI3K/Akt and the Ras-MAPK
cascades through both FAK-dependent and FAK-independent
pathways (43, 44). c-Src has also been implicated, in PC12 cells,
inNGF-induced down-regulation of EGF receptors. Expression
of dominant-negative c-Src blocked the tyrosine phosphoryla-
tion of mitogen-activated protein kinases (45). These results
prompt us to examine whether TrkC activates Ras-MAPK and
PI3K/Akt through the activation of c-Src. Here we show that
TrkC binds to and activates c-Src, and that inhibition of c-Src
activation blocks TrkC transforming activity and activation of
the PI3K/Akt and the Ras-MAPK cascades.
EXPERIMENTAL PROCEDURES
Cell Culture and Antibodies and Reagent—Mouse embry-
onic fibroblasts (MEF) deficient in c-Src, Yes, and Fyn (SYF) as
well as c-Src (SYF cells deficient for Yes and Fyn but overex-
pressing c-Src) cells were obtained from theATCC. 67NR, 4T1,
293T, and SYF cells were maintained in Dulbecco’s modified
Eagle’s medium plus 10% fetal bovine serum. Expression of Src
was frequently assessed by Western blot analysis. Antibodies
were obtained from the following companies: Anti-c-Src, anti-
TrkC, anti-HA(Y-11), anti-cyclinD1, and anti-Myc(9E10) from
Santa Cruz Biotechnology; anti-V5 from Invitrogen; anti-phos-
pho-Src, anti-phospho-MEK1/2, and anti-phospho-AKT from
Cell Signaling Technology; anti--actin from Sigma-Aldrich.
Pharmacological inhibitionwas performedwith the PI 3-kinase
inhibitor LY294002 (20 M) and c-Src family tyrosine kinase
inhibitor SU6656, both from Calbiochem.
Plasmids—Three siRNA-coding oligos against mouse c-Src
and IRS-1were designed and verified to be specific to c-src and
IRS-1 by Blast search against the mouse genome. To construct
hairpin-type single RNAi vectors, 5 l (100 mM) of the synthe-
sized sense and antisense oligonucleotides (Table 1) were com-
binedwith 1l of 1 MNaCl and annealed by incubation at 95 °C
for 2 min, followed by rapid cooling to 72 °C, and ramp cooling
to 4 °C over a period of 2 h. The c-src-siRNA-1 and c-src-
siRNA-2 insert were subcloned into the XbaI/XhoI sites of the
pFG12 lentivirus vector. A control siRNA, which does not
match any known mouse coding cDNA, was used as a control.
Immunoblotting and Immunoprecipitation—293T cells were
used for the detection of protein-protein interaction in vivo.
293T cells were transiently transfected with the indicated plas-
mids. After a 24-h transfection, cells were switched to 0.2%
serum overnight. Cells were lysed in a buffer containing 25 mM
Hepes (pH 7.5), 150mMNaCl, 1%Triton X-100, 10% glycerol, 5
mM EDTA, and protease inhibitor mixture (Complete, Roche
Applied Science, Gipf-Oberfrick, Switzerland). Extracts were
separated by SDS/PAGE followed by electrotransfer to polyvi-
nylidene difluoride membranes and probed with polyclonal or
monoclonal antisera, followed by horseradish peroxidase-con-
jugated anti-rabbit, anti-mouse IgG, respectively, and visual-
ized by chemiluminescence according to the manufacturer’s
instructions (Pierce). For immunoprecipitation, the cell lysates
were incubated with the appropriate antibody (Ab) for 1 h, fol-
lowed by incubation with Gamma-bind beads (Amersham Bio-
sciences) for 1 h at 4 °C. Beads were washed four times with the
buffer used for cell solubilization. Immune complexes then
were eluted by boiling for 3min in 2 Laemmli buffer (pH 6.8),
and then extracts were analyzed by immunoblotting as
described above.
Soft Agar Assays—Soft agar assays were performed according
to established protocols (29). 67NR and 4T1 and 67NR express-
ing activated c-Src or 4T1 cells carrying siRNA-coding oligos
against mouse c-Src and IRS-1 were seeded in triplicate at a
concentration of 8  103 cells/well in a 6-well plate. Bottom
layers were made up of 0.4% agar in 9% fetal bovine serum and
DMEM.Cells were resuspended in a top layer of 0.2% agar in 9%
fetal bovine serum and DMEM. Cells were fed every other day
by placing 2 drops of medium on the top layer. After 3 weeks at
37 °C, colonies were then stained with p-iodonitrotetrazolium
violet (1 mg/ml stock diluted at 1:500) for 16 h, and macro-
scopic colonies were counted (in quadruplicate). Each determi-
nation was done in triplicate.
Anchorage-independent Cell Growth—67NR and 4T1 were
seeded into an Ultra Low Cluster plate (ULC plate) (Corning
TABLE 1
siRNAs sequences for the mouse c-src gene and the mouse IRS-1 gene
Mouse c-Src-1 (pFG12 vector)
5-CTAGACCAGCCGCCAATATCCTAGTATTCAAGAGATACTAGGATATTGGCGGCTTTTTGGAAAC-3
Mouse c-Src-2 (pFG12 vector)
5-CTAGACCAAGATCACTAGACGGGAATCATTCAAGAGATGATTCCCGTCTAGTGATCTTTTTTTGGAAAC-3
Mouse IRS-1 515 (pFG12 vector)
5-CTAGACCAGAACCTGATTGGCATCTATTCAAGAGATAGATGCCAATCAGGTTCTTTTTTGGAAAC-3
Mouse IRS-1 1539 (pFG12 vector)
5-CTAGACCTAACCGGTTTCGAAAGAGATTCAAGAGATCTCTTTCGAAACCGGTTATTTTTGGAAAC-3
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Life Sciences, Acton, MA) at 1 106 cells and photographed at
96 h.
Viral Production and Infection of Target Cells—293T cells
were transfected with the transfer vector plasmid pCAG
(empty) or pCAG-TrkC plasmid and pCAG-v-Src with the
envelope-encoding plasmid pHCMVG, the packaging plasmid
pMDLg/pRRE, and the Rev-expression plasmid pRSV-Rev
using the calcium phosphate method. The supernatants were
harvested 48 and 72 h after transfection, pooled, passed
through a 0.45-m filter, ultracentrifuged for 2 h at 100,000
g in a SW28 rotor, resuspended in 100 l of 0.1% bovine serum
albumin in phosphate-buffered saline, and the lentiviral stocks
were stored in small aliquots at 80 °C for titration and cell
infection. SYF and SYF-Src cells were plated in 6-well plates
(1  105 cells/well) and were cultured overnight. Lentiviruses
were diluted in 2 ml of DMEM containing polybrene (8 g/ml)
and then centrifuged for 30 min at 1,500 rpm. After 24 h of
infection, polybrene-DMEM was replaced with fresh DMEM
medium, and the cells were cultured for other assays.
Reverse Transcription-PCRs—Mouse c-src RT-PCR for-
ward primer is GCATCATCCCAGCCAACTAT, and its RT-
PCR reverse primer is CAGCTGCATGAGGTTCTCAA.
Mouse IRS-1 RT-PCR forward primer is GGTGCTGCAGCT-
GATGAATA, and its RT-PCR reverse primer is CGAGATCT-
CCGAGTCAGTCC. Mouse GAPDH RT-PCR forward primer
is AAGGTCATCCCAGAGCTGAA, and its RT-PCR reverse
primer is CCCTGTTGCTGTAGC CGTAT. Total RNA was
extracted using a Quizol reagent
(Qiagen, Inc., Valencia, CA).
Reverse transcription was done
using a one step RT-PCR kit at the
suggested conditions (Qiagen, Inc.).
PCR products were separated on 1%
agarose gels and visualized by
ethidium bromide techniques.
RESULTS
TrkC Directly Binds to c-Src—We
examined the possibility that TrkC
may interact directly with c-Src in
vivo in a mouse mammary model
that consists of three distinct
tumor cell lines, 67NR, 4TO7, and
4T1. These cell lines are derived
from a single mammary tumor
that arose spontaneously in a wild-
type BALB/c mouse. 67NR cells
form primary tumors, but no tumor
cells are detectable in any distant
tissue. 4TO7 cells are able to spread
to the lung, but cannot establish vis-
ible metastatic nodules, whereas
4T1 cells are able to complete all
steps of metastasis and form visible
metastatic nodules in the lung effi-
ciently (46). The 67NR cell line had
negligible TrkC expression, but
TrkC is expressed in the 4TO7 and
4T1 cell lines (Fig. 1a). We have recently demonstrated that
TrkC was expressed 5–10-fold higher in 4T1 tumor cells com-
paredwith 4TO7 cells and that TrkC proteins in 4TO7 and 4T1
cells are tyrosine-phosphorylated, indicating an activated
state.3We determined the endogenous interaction of TrkC and
c-Src in 4T07 and 4T1 cells, which express endogenous TrkC.
To this end, we performed immunoprecipitation experiments
in 4T07 and 4T1 cells. Extracts prepared from 67NR cells were
used as negative controls. Endogenous TrkC was able to inter-
act with c-Src (Fig. 1a). We also examined the endogenous
interaction between TrkC and c-Src in Hs578T human breast
cancer cells which express TrkC. MCF7 human breast cancer
cells, which donot expressTrkC,were used as a control. Endog-
enous c-Src was able to interact with endogenous TrkC (Fig.
1b). To confirm this finding in a transient transfection system,
V5-tagged TrkC and HA-tagged c-Src were transfected into
293T cells. As shown in Fig. 1c, TrkC interacted strongly with
c-Src. We then determined whether expression of TrkC corre-
lates with certain pathological phenotypes in clinical breast
tumor samples, and wished to confirm that the above findings
are relevant to humanbreast tumors expressingTrkC.Todo so,
we examinedTrkC expression in invasive human breast tumors
by immunoblotting. Elevated expression of both TrkC and
c-Src was observed in infiltrating ductal carcinomas compared
with normal breast tissue samples (Fig. 1d), suggesting that
3 S.-J. Kim, submitted for publication.
FIGURE 1. TrkC interactswith c-Src. The expression of c-Src or TrkCwasmonitored as indicated. Identification
of endogenous TrkC-c-Src complexes in 4T07 and 4T1 cells (a) as well as in Hs578T cells (b) is shown. The cell
lysates were subjected to immunoprecipitation using anti-TrkC Ab, followed by immunoblottingwith anti-Src
antibody. Whole cell lysates also were probed for TrkC, c-Src, and -actin as a loading control. c, HA-tagged
c-Src and V5-tagged TrkC were transfected into 293T cells. Cell extracts were subjected to immunoprecipita-
tion using an anti-HA antibody and Gamma-bind beads, followed by immunoblotting with anti-V5 antibody.
d, identification of TrkC-c-Src complexes in human primary tumors. The protein of normal and primary breast
tumor tissue extracts from breast cancer patients were subjected to immunoblotting with anti-TrkC antibody
and Gamma-bind beads, followed by immunoblottingwith anti-c-Src, anti-phospho-c-Src, or anti-phosphoty-
rosine antibody. The endogenous -actin level was measured as an internal control.
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expression of bothTrkC and c-Srcmay contribute to the patho-
genesis of human invasive breast carcinomas. We therefore
screened for the presence of TrkC-c-Src complexes in human
breast tumors positive for the TrkC gene. Total tissue extracts
were isolated from primary tumors and subjected to immuno-
precipitation with the anti-c-Src antibody followed by immu-
noblotting with the anti-TrkC antibody. As shown in Fig. 1d,
TrkC-c-Src complexes were found in the human breast tumor
samples, but not in control breast tissue samples. TrkC expres-
sionwas associatedwith a strong increase in phosphorylation of
c-Src. These results clearly demonstrate that the interaction
between TrkC and c-Src occurs in vivo in human breast cancer
tissues expressing the TrkC gene.
SU6656 Treatment Suppresses TrkC Transformation Acti-
vity—We have recently demonstrated that inhibition of TrkC
expression completely blocks colony formation of 4T1 cells in
soft agar.3 This finding suggests that TrkC may induce the col-
ony formation of 4T1 cells through the activation of c-Src.
Therefore, we investigated whether the inhibition of c-Src
kinase activity blocks the colony formation of 4T1 cells using
SU6656 (47), an inhibitor of c-Src kinase. Upon the addition of
2 M SU6656, the colony formation of 4T1 cells was almost
completely suppressed indicated by the failure to form micro-
scopic or macroscopic colonies in soft agar when scored after
16 days (Fig. 2a).Most tumor cell lines formmulticellular sphe-
roids through cell-cell adhesion on non-adhesive agar-coated
dishes. Under these conditions, non-malignant cells generally
fail to do so and undergomassive cell death in culture (48). 4T1
cells readily form multicellular spheroids (49); however,
SU6656 treatment suppressed formation of multicellular sphe-
roids (Fig. 2b). This result suggested that TrkC and c-Src affect
the survival of 4T1 cells.
To see whether activation of c-Src can induce the colony
forming ability, we generated the stable 67NR cells expressing
v-Src, which is the constitutively active form of Src. Expression
of v-Src in 67NR cells was verified by immunoblotting using the
anti-V5 antibody (Supplemental Fig. S1a). And then we inves-
tigated whether v-Src increased the colony forming ability in
these cells. Expression of v-Src markedly increased formation
of microscopic or macroscopic colonies in soft agar when
scored after 20 days (Supplemental
Fig. S1b).
Characterization of the c-Src/
TrkC Interaction—c-Src is a mul-
tidomain protein containing an
unique N-terminal domain: UD
(residues 1–80), SH3 (residues
83–144), SH2 protein interaction
domains (150–247), a catalytic
region (269–522), and a negative-
regulatory tyrosine located near the
C terminus (residue 523) (50–52)
(Fig. 3a). To identify the functional
domain of c-Src responsible for the
interaction with TrkC, we used a
series of c-Src deletion constructs.
The c-Srcmutant lacking theN-ter-
minal domain (1–249) still inter-
acted with TrkC (Fig. 3b). This indi-
cates that the c-Src C-terminal
region (250–535) is directly in-
volved in this interaction. Next, we
tested the interaction of TrkC with
a series of C-terminal deletion
mutants. The c-Src C, which does
FIGURE 2. Inhibition of c-Src activation blocks soft agar colony formation
of 4T1 cells. a, soft agar colony-forming assay of mouse breast cancer cell
lines. Monolayer cells were trypsinized, washed, and plated in medium con-
taining 0.2% agar to assess anchorage-independent growth in the presence
or absence of SU6656 (1 M). Results are presented as the number of macro-
scopic colonies formed at 3 weeks after plating. b, 4T1 mouse breast cell line
as well as the control 67NR cell line were grown in medium containing 9%
serumandwere treatedwith vehicle control (dimethyl sulfoxide) and SU6656
(1M) for 3 days. Anchorage-independent spheroid growth of 67NR and 4T1
cells was then photographed in time at200 magnifications.
FIGURE 3. Identification of c-Src region responsible for the interaction with TrkC. a, schematic represen-
tation of full-length and truncated c-Src proteins. b, V5-tagged TrkCwas cotransfected into 293T cells with the
HA-tagged c-Src constructs. Cell extracts were subjected to immunoprecipitation using anti-HA antibody,
followed by immunoblottingwith anti-V5 antibody. The expression of c-Src or TrkC proteinswasmonitored as
indicated. c, immunoprecipitation analyses of overexpressed V5-TrkC and Myc-tagged c-Src proteins in 293T
cells.
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not have a negative-regulatory tyrosine in the C-terminal
region, still interacted with TrkC. While the deletion of amino
acid residues 361–535 (KD-1 andKD-2) also interactedwith
TrkC, the deletion of amino acid residues 275–360 abrogated
theTrkC interaction (Fig. 3c). These results clearly indicate that
the region including amino acids 275–360 of c-Src, which
includes the ATP binding domain, is required for TrkC
interaction.
The Fyn tyrosine kinase, amember of the c-Src kinase family,
is known to associate with IRS-1 in vitro and in vivo (53).
Because other members of the c-Src kinase family have similar
SH2 domains, these kinases may also associate with IRS-1 and
contribute to the overall response in various cellular back-
grounds. Because IRS-1 functions as the adaptor protein linking
ETV6-NTRK3 (Tel-TrkC) to downstream signaling pathways
(54), we examined whether the interaction between TrkC and
c-Src is mediated through IRS-1. 293T cells were transfected
with Myc-tagged c-Src and HA-tagged IRS-1 with or without
V5-tagged TrkC. IRS-1 interacts with either TrkC or c-Src (Fig.
4a). Three different domains in IRS-1 have been identified as
potentially contributing to insulin-like growth factor I receptor
(IGFIR) and insulin receptor binding: the pleckstrin homology
(PH) domain, the phosphotyrosine binding (PTB) domain, and
the SHC and IRS-1 NPXY binding (SAIN) domain (55). PH
domains bind phospholipids, therebymediating the interaction
of signaling proteins such as IRS-1 with the plasma membrane
(56). PTB domains in adaptor proteins bind to phosphorylated
tyrosines within NPXY motifs in interacting proteins such as
cell surface receptors (57), thus promoting receptor-adaptor
interactions. The SAIN domain of IRS-1 remains poorly char-
acterized but has been postulated to contain other potential
protein-protein interaction motifs (55, 58) (Fig. 4b). To deter-
mine the region of IRS-1 responsible for binding to c-Src,
lysateswere immunoprecipitatedwithMyc antibodies followed
by immunoblotting with HA antibodies. Myc-tagged c-Src was
able to interact with the IRS-1 construct containing the PTB
FIGURE4.TrkC interactswith c-Src and IRS-1.a, V5-taggedTrkCwas cotransfected into 293T cellswith theHA-tagged IRS-1 andMyc-tagged c-Src constructs.
Cell extractswere subjected to immunoprecipitationusing anti-HAantibody andGamma-bindbeads, followedby immunoblottingwith anti-V5 antibody. The
expression of c-Src, IRS-1, or ENwasmonitored as indicated. b, schematic representation of full-length and truncated IRS-1 proteins is shown. c–f, PTB domain
of IRS-1 is important for association with c-Src and TrkC. Myc-tagged c-Src was cotransfected into 293T cells with HA-tagged IRS-1. g, identification of c-Src
domain interacting with IRS-1. h, IRS-1-truncated constructs and V5-tagged TrkC were cotransfected into 293T cells. Cell extracts were subjected to immuno-
precipitation using anti-HA antibody, followed by immunoblotting with anti-V5 antibody.
c-Src Mediates Akt Activation by TrkC
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domain (HA-IRS-1C, HA-IRS-1D, and HA-IRS-1) (Fig. 4, c–f).
Only the fragment consisting of the IRS-1 PH domain alone
(IRS-1B) was incapable of associating with Myc-tagged c-Src,
indicating that the PTBdomain of IRS-1 is required for its inter-
actionwith c-Src.Also, to determine the region of c-Src respon-
sible for binding to IRS-1, lysates were immunoprecipitated
with HA antibodies followed by immunoblotting with Myc
antibody. HA-tagged IRS-1 was able to interact with Myc-
tagged c-Src constructs containing the C-terminal region
(254–535) (SH3,SH2) (Fig. 4g). We also attempted to deter-
mine the region of IRS-1 responsible for binding to TrkC.
Lysates were immunoprecipitatedwithHAantibodies followed
by immunoblotting with V5- antibodies. V5-tagged TrkC was
able to interact with all IRS-1 constructs containing the PTB
domain (HA-IRS-1C, HA-IRS-1D, and HA-IRS-1) (Fig. 4h),
indicating that the PTB domain of IRS-1 is also required for its
interaction with TrkC.
c-Src Expression in c-Src-deficient MEF Cells Enhances the
TrkC-IRS-1 Complex Formation—To test whether TrkC bind-
ing to IRS-1 requires c-Src, we used SYF cells that were derived
from Src, Yes, and Fyn triple knock-out mouse embryos (59).
Because Src, Yes, and Fyn are three ubiquitously expressed
members of the Src family tyrosine kinases, no Src family tyro-
sine kinase activity was detected in these SYF cells.We infected
SYF and SYF-c-Src cells with the lentiviral vector transducing
TrkC gene. As shown in Fig. 5, a and b, expression of TrkC
protein in these cells was verified by immunoblotting using the
anti-V5 antibody. We next determined whether TrkC-IRS-1
complex formation is increased in the presence of c-Src. IRS-1
andTrkC complexes were detected in c-Src-deficient SYF cells.
However, the level of IRS-1 immunoprecipitated with TrkC
was markedly enhanced in SYF cells
expressing c-Src compared with
that in SYF cells (Fig. 5c), even
though level of endogenous IRS-1 is
significantly lower in SYF-c-Src
cells compared with SYF cells.
These results suggest that c-Src
mediates the TrkC-IRS-1 interac-
tion. To see whether IRS-1 is also
required for transforming activity of
4T1 cells, the RNA interference
approach was employed to knock-
down endogenous IRS-1 in 4T1
cells. We constructed lentiviral vec-
tors expressing two different IRS-1
siRNAs (1 and 2). To establish cell
lines expressing these IRS-1 siRNA
genes, two cycles of infection and
selection were performed. Silencing
of IRS-1 in 4T1 cells was confirmed
by RT-PCR. Expression of IRS-1
siRNAs (1 and 2) resulted in over
80–90% decreases in the expression
of endogenous IRS-1 (Supplemental
Fig. S2a). The luciferase RNAi
nucleotide (siLuc) was used as a
control. Expression of IRS-1 siRNAs
slightly decreased formation of microscopic or macroscopic
colonies in soft agar when scored after 20 days, suggesting that
IRS-1 may contribute to the transforming activity in 4T1 cells
(Supplemental Fig. S2b).
To investigate whether TrkC modulated the c-Src expres-
sion, we examined the expression of c-Src in SYF-SRc cells
expressing TrkC and 4T1 cells expressing siTrkC by RT-PCR.
c-Src transcript was not affected by the expression of TrkC in
SYF-Src cells, but c-Src protein expression was slightly
decreased compared with the control cells (Fig. 5, d and e).
However, c-Src phosphorylation levels were markedly
increased in SYF-Src stably expressing TrkC cells, suggesting
that TrkC activates c-Src in these cells (Fig. 5e). Consistent with
this finding, we found that c-silencing of TrkC in 4T1 cells
markedly decreased c-Src phosphorylation levels (Fig. 5f).
Effects of c-Src-targeted siRNA on Transformation of 4T1
Cells—We have recently demonstrated that inhibition of
TrkC expression markedly suppresses the colony formation
of 4T1 cells.3 To see whether inhibition of c-Src is also
required for transforming activity of 4T1 cells, the RNA
interference approach was employed to knockdown endog-
enous c-Src in 4T1 cells. We constructed lentiviral vectors
expressing two different c-Src siRNAs (1 and 2). To establish
cell lines expressing these c-Src siRNA genes, two cycles of
infection and selection were performed. The c-Src gene
silencing activity of c-Src RNAi in 4T1 cells was confirmed by
immunoblotting with c-Src antibodies. Expression of c-Src
siRNAs (1 and 2) resulted in over 80% decreases in the expres-
sion of endogenous c-Src (Fig. 6a). The luciferase RNAi nucle-
otide (Si-Luc) was used as a control. In the previous study, we
have shown that TrkC is responsible for the elevated activa-
FIGURE5. c-Src expression in c-Src-deficientMEFcells enhances theTrkC-IRS-1 complex formation.a and
b, expression of TrkC protein was examined by immunoblotting in SYF and SYF-Src cells expressing EN. c, cell
extracts were subjected to immunoprecipitation using anti-V5 antibody and Gamma-bind beads, followed by
immunoblotting with anti-IRS-1 antibody. The expression of V5-TrkC or IRS-1 was monitored as indicated.
d, expression of c-srcmRNA in control and TrkC expressing SYF-Src cells was examined by RT-PCR. The endog-
enous GAPDH mRNA level was measured as an internal control. e, TrkC increased phosphorylation of c-Src in
vivo in control and TrkC expressing SYF-Src cells. Cell lysateswere probed for c-Src andphosphorylated c-Src as
well as -actin as a loading control. f, silencing of TrkC decreased c-Src phosphorylation. Phosphorylated c-Src
and total c-Src proteinswere examined by immunoblotting in 4T1 cells stably expressing control-siRNA (siLuc)
and siTrkC-siRNA.
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tion of the Mek1 and Akt in 4T1 cells. Therefore, we exam-
ined whether c-Src activation is involved in the TrkC-in-
duced Mek1 and Akt activation as well as cyclin D1
expression. As shown in Fig. 6b, TrkC-induced Mek1 and
Akt activation as well as cyclin D1 expression were signifi-
cantly reduced in c-Src knockdown cells. Expression of c-Src
RNAi nucleotides (Si-c-Src) failed to form microscopic or
macroscopic colonies in soft agar when scored after 16 days
(Fig. 6c). We then examined whether v-Src reverses the
effect of TrkC knockdown on colony forming ability of 4T1
cells. To do so, we infected 4T1-siTrkC cells with the recom-
binant lentiviral vector carrying a v-Src cDNA or empty vec-
tor as a control. Expression of the predicted v-Src protein in
transformed 4T1-siTrkC cells was verified by immunoblot-
ting using the anti-V5 antibody (Fig. 6d). Expression of v-Src
markedly increased colony formation in 4T1-siTrkC cells
(Fig. 6e), suggesting that c-Src plays an important role in
TrkC-induced colony formation.
To see thewhether increasing levels of TrkC further activates
Akt, we transfected TrkC in T-47D tet-on cell lines and exam-
ined the Akt activation. We found that levels of activated Akt
correlated with level of TrkC expression. We also demon-
strated that levels of c-Src associated with TrkC and levels of
phosphorylated c-Src were also increased when TrkC expres-
sionwas induced (Fig. 6f). Taken together, our data suggest that
c-Src plays a role in the TrkC-inducedMEK1/2 and Akt activa-
tion and cyclin D1 expression and mediates the TrkC transfor-
mation activity.
FIGURE 6.Suppressionof c-Src expressionby stable siRNA reduces the level ofMEKphosphorylation, AKTphosphorylation, and cyclinD1expression
in 4T1 cells. a, suppression of c-Src expression by stable siRNA. Expression of phosphorylated c-Src and c-Src proteinwas examinedby immunoblotting in 4T1
cells stably expressing control-siRNA, c-Src-siRNA-1, and c-Src-siRNA-2. b, suppression of c-Src expression by stable siRNA decreases levels of phosphorylated
AKT, phosphorylated MEK, and cyclin D1 in 4T1 cells. c-Src-siRNA-expressing 4T1 or control 67NR cells were serum-starved overnight in 0.5% serum and then
stimulated with and without 9% CS/DMEM for 1 or 6 h. Whole cell lysates were prepared for Western blotting and probed with antibodies against the
phosphorylated forms of Mek1/2 (Ser217/221), phosphorylated Akt (Ser473), and cyclin D1. c, soft agar colony-forming assay. Soft agar colony-forming assay of
4T1 control-siRNA, 4T1 c-Src-siRNA-1, and EN c-Src-siRNA-2. Monolayer cells were trypsinized, washed, and plated in medium containing 0.2% agar to assess
anchorage-independent growth. Results are presented as the number of macroscopic colonies formed at 3 weeks after plating. d, expression of v-Src was
examined by immunoblotting in 4T1-siTrkC cells stably expressing control and v-Src. e, v-Src reverses the effect of TrkC knockdown on colony forming ability
of 4T1 cells. Soft agar colony-forming assay of 4T1-siTrkC cells expressing either control or v-Src. Results are presented as the number ofmacroscopic colonies
formedat 3weeks afterplating. f, inductionof TrkCexpressionbydoxycycline increased the level of c-Srcbound toTrkC inT-47D tetoncells. Cellswere cultured
for 0–48h in thepresence (2g/ml) and absence of doxycycline. Cell extractswere subjected to immunoprecipitation using anti-c-Src antibodyor anti-mouse
IgG, followed by immunoblotting with anti-V5 antibody. Expression of V5-TrkC, c-Src, phosphorylated c-Src, and phosphorylated AKT was monitored as
indicated.
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c-Src Is Required for TrkC-induced Mek1 and PI3K/Akt-1
Activation and Cyclin D1 Expression inMEF Cells—To test the
role of c-Src on the Mek1 and PI3K-Akt pathways in TrkC
signaling, we investigated the activation ofMek1 and PI3K-Akt
by TrkC in SYF and SYF-c-Src cells. To do so, we constructed a
lentiviral vector expressing the TrkC. To establish cell lines
expressing this TrkC gene, two cycles of infection and selection
were performed. TrkC expression in SYF and SYF-c-Src cells
was confirmed by immunoblotting with TrkC antibody. SYF
cells and SYF-c-Src cells with or without TrkC were serum-
starved overnight and then incubated with serum. The phos-
phorylated c-Src was only detected in SYF-c-Src cells (Fig. 7, a
and b). Interestingly, in SYF cells expressing TrkC, phosphoryl-
ated proteins recognized by anti-phospho-c-Src antibody were
detected. This suggests that other c-Src familymembers, which
are also recognized by anti phospho-c-Src antibody, may be
activated by TrkC.
TrkC signaling is known to induce phosphorylation of the
Ras/MAPK andPI3K/Akt (60). To elucidatewhich intracellular
pathways could be involved in c-Src-mediated TrkC signaling,
we assessed the degree of activation of the Ras/MAPK and
PI3K/Akt pathways in SYF and SYF-c-Src cells expressing
TrkC. Cells were assayed before and after serum stimulation for
Mek1 and Akt activation byWestern blot analysis of whole cell
lysates using antibodies directed against the phosphorylated
(activated) forms of these antibodies. As shown in Fig. 7c, Mek1
and PI3K/Akt activation as well as cyclin D1 expression were
not observed in SYF cells. TrkC expression did not activate Akt
in SYF cells. However, stable expression of TrkC in SYF-c-Src
cells led to Akt phosphorylation in response to serum stimula-
tion, suggesting that TrkC-induced PI3K-Akt activation
requires c-Src (Fig. 7d). In both SYF and SFY-c-Src cells,
expression of TrkC increased Mek1 phosphorylation even in
the absence of serum (Fig. 7, c and d). SYF cells expressing TrkC
exhibited constitutively high levels of cyclin D1 even after over-
night serum starvation (Fig. 7c). SYF-c-Src cells responded to
TrkC, showing cyclin D1 elevation in the presence of serum
(Fig. 7d). These genetic data demonstrated that c-Src is
required for TrkC-induced PI3K/Akt activation.
DISCUSSION
The results of this study demonstrate that c-Src mediates
TrkC-induced activation of the PI3K/Akt pathway. TrkC
directly interacts with c-Src. Knockdown of c-Src suppressed
activation of the PI3K/Akt pathway and markedly decreased
the transforming activity of 4T1 cells which express endoge-
nous TrkC. Finally, we also demonstrated that TrkC failed to
activate the PI3K/Akt pathway in c-Src-deficient SYF cells.
The Trk family of neurotrophin receptors is emerging as an
important player in carcinogenic progression. Trks appear to
have a high capacity for ligand-independent activation, pre-
sumably via spontaneous interactions. Recent studies have
identified correlations between biological responses and the
activation of selective intracellular signaling pathways medi-
FIGURE 7. c-Src is required for TrkC-inducedAkt activation in Src-deficientMEF cells. a and b, to generate SYF or SYF-c-Src cell lines stably expressing TrkC
were infected with lentiviruses containing control vector alone (pCAG) or TrkC. Successful expression of TrkC was determined using anti-TrkC antibody.
TrkC-expressing SYF and SYF-c-Src cells exhibit elevated levels of phosphorylated Src. c, TrkC-expressing SYF cells exhibit elevated levels of phosphorylated
Mek1 and cyclin D1, but not phosphorylated Akt. d, TrkC-expressing SYF-c-Src cells exhibit elevated levels of phosphorylated Mek1, phosphorylated Akt, and
cyclin D1. TrkC-expressing or control SYF cells and TrkC-expressing or control SYF-c-Src cells were serum-starved overnight in 0.5% serumand then stimulated
with () and without () 9% calf serum/DMEM for 1 or 6 h. Whole cell lysates were prepared for Western blotting and probed with antibodies against the
phosphorylated forms of Mek1/2 (Ser217/221), phosphorylated Akt (Ser473), cyclin D1, and -actin (as a loading control). Data are representative of three
experiments.
c-Src Mediates Akt Activation by TrkC
1398 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 3•JANUARY 18, 2008
 at Y
O
N
SEI U
N
IV
ERSITY
 on O
ctober 29, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ated by TrkC (60). TrkC is known to activate intracellular sig-
naling cascades, including the Ras/Erk pathway and the PI3K/
Akt pathway (60–62). The Ras/Erk pathway plays an essential
role in neuronal differentiation. In contrast, the PI3K/Akt path-
way is essential for progenitor survival. These findings suggest
that both Ras/Erk pathway and the PI3K/Akt pathway play a
significant role inTrkC-mediated oncogenesis. This hypothesis
is also supported by a previous study of ETV6-NTRK3 (Tel-
TrkC) (42). Both the Ras/Erk and PI3K/Akt pathways appear to
be essential for transformation and cell cycle progression in
ETV6-NTRK3-expressing cells. Aberrant activation of the Ras/
Erk pathway is known to be associated with cellular transfor-
mation (63, 64). Alterations in the PI3K-AKT pathway have
also been observed in humans tumors (65, 66). Although these
andother studies illustrate the oncogenic potential of each indi-
vidual pathway, it is becoming increasingly clear that a syner-
gistic effect exists between the Ras-Erk1/2 and PI3K-Akt cas-
cades in transformation. In the present investigation, we found
that c-Src is required for TrkC-induced activation of the PI3K/
Akt pathway. These data place c-Src upstream of PI3K/Akt and
provide amechanism of TrkC-induced cellular transformation.
All Src family members are composed of several well-char-
acterized protein domains. c-Src is a multidomain protein and
consists of an N-terminal membrane targeting signal, a SH3
domain, a SH2 domain linked to the kinase domain, and a
C-terminal tail (67). The catalytic domain is well conserved in
all members of the c-Src family. The catalytic domain, which is
responsible for the catalytic activity of the molecule, contains
many subdomains that are closely related to the serine-threo-
nine kinases, including the ATP-binding pocket. Analysis of a
series of c-Src deletion mutants for TrkC binding domain
revealed that amino acids 274–360 of c-Src is responsible for
TrkC binding. This association is presumed to initiate c-Src
activation, by allowing the molecule to adopt the catalytically
active conformation. However, this hypothesis requires further
experiments for validation. Recent studies suggest that the acti-
vation of the Src family tyrosine kinases by receptor tyrosine
kinases may be more complex than simple recruitment. For
example, the activation of c-Src by epidermal growth factor
receptor in transfected cells requires the small GTPases Ras
and Ral (68). There is also a role for the tyrosine phosphatase
Shp2 in promoting the activation of Src family tyrosine
kinases in response to growth factors (69). A more recent
report suggests that Shp2 may be involved in TrkC-induced
c-Src activation (70). The fibroblast growth factor (FGF)
receptor substrate 3 (FRS3) binds all neurotrophin Trk
receptor-tyrosine kinases and becomes tyrosine-phospho-
rylated in response to NGF, BDNF, and NT-3 stimulation.
The signaling molecules Grb2 and Shp2 bind FRS3 and Shp2,
in turn, becomes tyrosine-phosphorylated.
IRS-1 contains 21 putative tyrosine phosphorylation sites,
several of which are located in amino acid sequence motifs that
bind to SH-2 domain proteins, including the p85 regulatory
subunit of PI 3-kinase, Grb-2, Nck, Crk, Fyn, Csk, phospho-
lipase C, and Shp2 (55–58). IRS-1 contains also30 potential
serine/threonine phosphorylation sites in motifs recognized by
various kinases such as casein kinase II, protein kinase C, PI3K/
Akt, and MAP kinases. In this report, we have shown that the
C-terminal region of c-Src interacts with IRS-1. However, it
remains to be clarified whether the TrkC binding domain in
c-Src overlaps with the IRS-1 binding domain in c-Src.We also
cannot exclude the possibility that c-Srcmediates complex for-
mation between IRS-1 and TrkC. This hypothesis is supported
by the finding that the level of IRS-1 immunoprecipitated with
TrkC was markedly enhanced in SYF cells expressing c-Src
compared with that in c-Src-deficient SYF cells (Fig. 5c).
Another possibility is that TrkC may directly, but weakly,
interact with IRS-1. It is possible that an unidentified protein
may also be involved in the TrkC-IRS-1 complex formation.
Alterations in the PI3K/AKT pathway have also been
observed in humans tumors, including amplification of the
AKT  isoform in breast and ovarian carcinomas (71) and
amplification of the PI3K regulatory subunit in ovarian carci-
noma (66) Although these and other studies (reviewed in Ref.
20) illustrate the oncogenic potential of each individual path-
way, it is becoming increasingly clear that a synergistic effect
exists between the Ras/MAPK and PI3K/Akt cascades in trans-
formation. Recent studies suggest that depletion of endogenous
c-Src levels by means of siRNA or expression of dominant-
negative c-Src significantly reduced cell proliferation in vitro,
and led to a clear decrease in Akt phosphorylation, placing
c-Src upstream of the PI3 kinase/Akt signals. Taken together,
our observations establish an essential role for c-Src kinase in
activation of the PI3K/Akt cascade in TrkC-expressing cells.
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